The Top Five Biotech Innovations of the 2000s
Opinion
[Editor’s Note: As the decade comes to an end, we’ve asked a number of Xconomists around the country to weigh in with the Top 5 innovations they’ve seen in their respective fields the past 10 years, or the Top 5 disruptive technologies that will impact the next decade. Here’s the first installment.]
Here are the 5 biotech innovations from this decade that are currently (or will be shortly) making a big difference for patients with a variety of diseases.
1) Cancer therapies such as Roche/Genentech’s trastuzumab (Herceptin) and Celgene’s lenalidomide (Revlimid).
2) HIV therapies such as Gilead Sciences’ combination of efavirenz, emtricitabine, and tenofovir (Atripla).
3) Improved flu vaccines.
4) Therapies for hepatitis C such as Vertex Pharmaceuticals’ telaprevir.
5) Tumor vaccines such as Dendreon’s sipuleucel-T (Provenge).
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.
4 responses to “The Top Five Biotech Innovations of the 2000s”
Underwriters and Partners
Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Success or failure depends on you. Get advice from the experts to help your startup succeed
From Our Editors · Video
Interview with David Berry on Microbiome Therapeutics
Video interview with David Berry, general partner at Flagship Pioneering.
The Threat of a Black Market Within the Market
The Hidden Risks of Sourcing Human Biological Samples
Scientist.com
See How We’re Investing to Change Healthcare for the Better.
Providence Ventures shares its advice on making successful invest
Providence Ventures
What about Gleevec?
Dave—I was waiting for someone to chime in with that one. I’m guessing Clay would probably lump that in with his first point about the big cancer drugs of the decade. Other tech leaders that I’m canvassing keep mentioning Gleevec, so that definitely shouldn’t be overlooked.